Astellas to acquire eye drug developer Iveric Bio for $5.9B

[cafead]

via Japanese drugmaker Astellas Pharma on Sunday agreed to acquire Iveric Bio for about $5.9 billion, betting that a medicine the biotechnology company has developed for a common type of vision loss can help it build an eye drug business.

article source